NCT04387916
A Study of KC1036 in Patients with Advanced Solid Tumors
StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary completion date: Jul 31, 2023 to Oct 31, 2025
- Study completion date: Jul 31, 2024 to Dec 31, 2025
- Site contacts updated at 3 of 3 sites
- Notable Primary completion date: Jul 31, 2022 to Jul 31, 2023
- Study completion date: Jul 31, 2023 to Jul 31, 2024
- Notable Enrollment target: 108 to 207
- Eligibility criteria shortened, about 30 words
- Study sites: 1 to 3
- Secondary endpoints: 8 to 9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 31, 2020 to Sep 4, 2020
- Site details revised
- Study title shortened, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum tolerated dose (MTD)
Timeframe: First 4 weeks after initial administration of KC1036
Adverse events (AEs)
Timeframe: From enrollment up to 30 days after last dose
Secondary (9)
Pharmacokinetics (PK) profile: Cmax
Pharmacokinetics (PK) profile: Tmax
Pharmacokinetics (PK) profile: T1/2
Pharmacokinetics (PK) profile: AUC0-t and AUC0-∞
Objective Response Rate (ORR)
Show 4 moreShow less
Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Overall Survival (OS)
Arms and interventions
KC1036Experimental
Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
Drugs: KC1036
Sites
3 sites in 1 country